Arcus Biosciences (NYSE:RCUS) CEO Terry Rosen Sells 28,947 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CEO Terry Rosen sold 28,947 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $633,360.36. Following the completion of the sale, the chief executive officer directly owned 2,220,553 shares in the company, valued at $48,585,699.64. This trade represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Arcus Biosciences Price Performance

Shares of NYSE:RCUS opened at $22.02 on Friday. Arcus Biosciences, Inc. has a 1-year low of $6.50 and a 1-year high of $26.40. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The business has a fifty day moving average price of $20.96 and a 200-day moving average price of $14.04. The company has a market capitalization of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The company had revenue of $26.00 million for the quarter, compared to analysts’ expectations of $19.89 million. During the same quarter in the previous year, the business posted ($1.00) EPS. Arcus Biosciences’s revenue was down 45.8% compared to the same quarter last year. As a group, equities analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RCUS has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. Wedbush set a $35.00 price target on Arcus Biosciences and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Truist Financial set a $30.00 price objective on Arcus Biosciences in a research report on Friday, December 12th. The Goldman Sachs Group boosted their target price on Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday, October 30th. Finally, Wells Fargo & Company upped their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, October 20th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.89.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after purchasing an additional 1,021 shares during the period. SBI Securities Co. Ltd. boosted its holdings in shares of Arcus Biosciences by 13,547.6% in the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after buying an additional 2,845 shares during the last quarter. CWM LLC grew its position in Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after buying an additional 3,810 shares during the period. Ameritas Investment Partners Inc. increased its holdings in Arcus Biosciences by 34.3% during the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after buying an additional 1,796 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Arcus Biosciences by 440.3% in the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock worth $62,000 after acquiring an additional 6,191 shares during the period. Institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.